Don't forget to drop the mike after saying it's the ultimate, best-est ever.
They are buying hand over fist.
I probably shouldn't shout.
get busy spam a lot
humongous amounts. You got 4 points today after dozens of posts- considering all the margin calls you've gotten making you cover at nosebleed levels, just unfair. Give it up, it ain't coming back down.
By the way I hope it does.
Thinks he's moving the market.
One of the rumors floating was that AGIO had targeted similar enzymes with no luck and recently data started surfacing from their studies.(Don't believe this myself) I can't find any reports that the preclinical data they released was bad. Hard to determine anything at this point, but the question does arise as to why AGIO isn't expanding and trying to dominate some easy to target parallel therapeutics in their own field so that they can monopolize the tumor metabolism field.
You'll probably have to read the posters and scientific papers to make any sort of judgement. Basically the invitro data can be summed up as there being enough evidence to investigate CAL's drugs clinically.
Same strategy for both. 93k for DNDN provenge treatment that extends treatment for a few months. Der, but it is the only viable immunotherapy for cancer right chartguy et.al.
Hell, just sellout of NXPI all together
A more realistic median overall survival of nine to 10 months for GBM rapid progressing patients treated with DCVax means there is no benefit over existing therapy. Northwest Bio could not claim DCVax is benefiting these patients at all.
The problem is the data were compiled and analyzed outside of a clinical trial, which leaves conclusions susceptible to biases, intentional or not. Northwest Bio asserts the new data show DCVax-treated patients, all with glioblastoma multiforme (a form of brain cancer) are living longer than expected compared to historical controls. But I can easily take the same data presented Friday and demonstrate DCVax patients are living no longer than you'd expect to see from published studies.
Last Friday's presentation encompasses 51 newly diagnosed GBM patients who sought entry into Northwest Bio's ongoing phase III study but were deemed ineligible because of evidence their brain tumors were re-appearing despite six weeks of radiation and chemotherapy. In order to participate in Northwest Bio's phase III study, GBM patients were required to have stable disease before randomization to DCVax or a placebo. These 51 GBM patients didn't meet that criteria and were therefore ineligible, but Northwest Bio treated them all with DCVax anyway and tracked their performance outside of the phase III trial.
f you add the two "indeterminate" patients and three "unclassified" patients -- all dead within 10 months -- to the 20 GBM rapid progressors, the median overall survival for rapid progressors falls to approximately nine to 10 months, not the 15.3 months claimed by Northwest Bio in Friday's presentation, according to my calculations. (Do the median calculation yourself, you'll arrive at the same answer.)
A more realistic median overall survival of nine to 10 months for GBM rapid progressing patients treated with DCVax means there is no benefit over existing therapy. Northwest Bio could not claim DCVax is benefiting these patients at all. Less
Kite and Juno: Will likely move in similar directions to ADXS use of antibody tumor suppressor blocking:
No reason to expect solid tumors will not be responsive at this point or that the sensitivity or range of other platforms makes them invaluable..
Co presented on a preclinical study evaluating the therapeutic potential of ADXS-HPV in combination with anti-OX40 and anti-GITR antibodies . The data demonstrated that the combination of therapies led to significant inhibition of tumor growth and prolonged survival in tumor bearing mice. Complete regression of established tumors occurred in 40% and 60% of animals treated with ADXS-HPV in combination with anti-OX40 and anti-GITR antibodies, respectively.
Co presented preliminary data from an ongoing Phase 1 clinical study of 10 companion dogs with osteosarcoma. The data suggests that ADXS-HER2 in combination with palliative radiation delayed tumor progression and prolonged overall survival in pet dogs with spontaneous osteosarcoma that were not candidates for primary tumor removal (amputation). Repeat doses of ADXS-HER2 were well tolerated with no systemic or cardiac toxicity. Additionally, the combination treatment was found to maintain or improve limb function and quality of life over the study period.
Co presented a preclinical study evaluating the therapeutic potential of ADXS-HPV in combination with anti-PD-L1 antibody in mice. The data indicated that co-administration of ADXS-HPV with anti-PD-L1 antibody demonstrated an improved ability to control tumor growth compared with anti-PD-L1 antibody therapy alone. The combination was well tolerated with no added toxicities.